Mandate

Vinge has advised Main Capital and Björn Lundén in connection with the acquisition of Due Compliance AB

Due Compliance is a software company which enables organisations to comply with the requirements in relation to Money Laundering and Terrorist Financing (Prevention) Act by providing digital tools for AML, KYC and Risk Assessments.

Björn Lundén, which is a strong provider of software for accounting, invoicing and payroll management, considers the acquisition of Due Compliance as an important step towards expanding its offering of digital tools in the regulatory market. The acquisition strengthens the group’s market position with the goal of becoming a leading player in Europe offering a comprehensive set of cloud-based accounting, ERP and RegTech solutions.
Vinge’s team consisted of Filip Öhrner, Josef Groow (M&A), Arvid Weimers, Karl-Gustaw Tobola, August Ahlin (Banking and Finance), Lisa Hörnqvist (IT and GDPR), Axel Lennartsson (IP), Victor Björkheim (employment) and Jessica Öijer (Transaction Support Senior Specialist).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026